Back
ESC Premium Access

Treatment persistence of patients with atrial fibrillation on VKA or NOAC: Data from GLORIA-AF Phase III 1-year interim analysis

Session: Poster Session 5 - Atrial fibrillation and oral anticoagulation 5
Topic: Oral Anticoagulation
Speaker: Professor G. Lip (Liverpool, GB)
Event: ESC Congress 2019

Congress Presentation

About the speaker

Professor Gregory Yh Lip

University of Liverpool, Liverpool (United Kingdom of Great Britain & Northern Ireland)
92 presentations
9 followers

8 more presentations in this session

Direct comparison of dabigatran, apixaban, rivaroxaban and edoxaban for effectiveness and safety among patients with non-valvular atrial fibrillation

Speaker: Doctor E. Choi (Seoul, KR)

Access
Abstract
Thumbnail

Efficacy and safety of dronedarone by duration of atrial fibrillation history: a post-hoc analysis of the ATHENA trial

Speaker: Professor C. Blomstrom-Lundqvist (Orebro, SE)

Access
Abstract
Slides
Thumbnail

Clinical characteristics and 1-year outcomes in atrial fibrillation patients with or without history of intracranial haemorrhage treated with edoxaban: snapshot analysis of the Global ETNA-AF program

Speaker: Professor P. Kirchhof (Hamburg, DE)

Access
Abstract
Thumbnail

Dual antithrombotic therapy is similarly effective to triple therapy in preventing thrombotic events in patients with atrial fibrillation and acute coronary syndrome

Speaker: Professor Z. Motovska (Prague, CZ)

Access
Abstract
Slides
Thumbnail

Use of direct oral anticoagulants in patients with atrial fibrillation having a history of intracranial hemorrhage

Speaker: Doctor T. Chao (Taipei, TW)

Access
Abstract
Thumbnail

Access the full session

Poster Session 5 - Atrial fibrillation and oral anticoagulation 5

Speakers: Professor G. Lip, Doctor E. Choi, Professor C. Blomstrom-Lundqvist, Professor P. Kirchhof, Professor Z. Motovska...
Access
Thumbnail

About the event

Image

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb